Early decisions. Disciplined execution
First-in-patient, run with senior oversight.
Early clinical studies create decisions that shape the rest of a development program. The operational plan must protect participants, generate interpretable data and stay disciplined enough that emerging safety or feasibility signals can be acted on quickly.
MDTrials CRO supports early patient-cohort and first-in-patient studies through Canadian regulatory start-up, operational feasibility, site execution, monitoring and project oversight.
Feasibility to close-out, fully covered
What we can support
- Protocol operational review and feasibility before site assumptions are locked
- Health Canada clinical-trial application preparation/support and post-authorization regulatory maintenance within agreed scope
- Research-ethics coordination and site start-up
- Site identification, qualification and activation
- Coordination of medical monitoring, safety workflows and specialist service providers where required
- Risk-based monitoring and issue escalation proportionate to the study
- Trial master file / essential-document oversight within contracted scope
- Close-out, reconciliation and archival planning
Where we fit and where we do not
MDTrials CRO does not operate a dedicated healthy-volunteer clinical pharmacology unit. Our early-phase positioning is centered on first-in-patient and early patient-cohort execution through qualified investigational sites, with specialist facilities or partners added when the protocol requires capabilities we do not own.
If a program requires a bedded healthy-volunteer unit, intensive clinical pharmacology infrastructure, or another specialized facility outside our scope, we will say so at feasibility rather than imply otherwise.
Dose escalation and safety oversight
Early-phase studies with dose escalation require a defined medical oversight model before the first participant is dosed: who reviews emerging safety data, how dose-limiting toxicities are adjudicated, how a safety review committee is convened and documented, and how escalation decisions are recorded.
When medical monitoring is included in the MDTrials scope, the medical-oversight model is defined during scoping and delivered by an appropriately qualified medical monitor under documented responsibilities. Sponsors may also retain their own medical monitor or safety provider, which MDTrials will integrate into the operating model.
Canada-focused regulatory execution
Clinical trials in Canada are conducted under Health Canada requirements and Good Clinical Practice. Health Canada implemented ICH E6(R3) in April 2026, reinforcing proportionate quality management, documented service-provider responsibilities and oversight of computerized systems and trial data. MDTrials builds those expectations into start-up rather than treating them as end-of-study documentation. [R17–R20]
Frequent Questions
- Can a Phase 1 trial run in Canada without a dedicated Phase 1 unit?For first-in-patient and early patient-cohort studies, yes — these are conducted at qualified investigational sites with appropriate infrastructure rather than in a bedded pharmacology unit. Studies requiring intensive healthy-volunteer confinement do need a dedicated unit, and we will tell you at feasibility if that applies to your protocol.
- Who provides medical monitoring for an early-phase study?When medical monitoring is included in the MDTrials scope, the medical-oversight model is defined during scoping and delivered by an appropriately qualified medical monitor under documented responsibilities. Sponsors may also retain their own medical monitor or safety provider, which MDTrials will integrate into the operating model.
- How quickly can a Canadian early-phase study start up?Timelines depend on the Health Canada review pathway, the research ethics board of record, contracting and site readiness. We give an indicative timeline at feasibility based on the actual pathway for your study rather than a generic figure.
CONTACT US
MDTrials CRO runs early patient-cohort and first-in-patient studies in Canada, with explicit boundaries around what is and isn't owned.